Patient Research for RRMS – Newly diagnosed and switchers of medications

Stuart SchlossmanMS Research Study and Reports

Patient Research for RRMS – oral or injectables.


Find a Cure Panel (FACP)  specializes in patient research for
rare and serious diseases and has some upcoming research for people with MS


This
research focuses on your decision for which treatment you commenced (i.e. oral
vs. injectable vs. infusion) as well as reasons for switching or potentially
switching to another treatment and the decision calculus for such switch.


To
qualify for this survey, you must meet the following qualifications:

  • Have RRMS and be on oral
    (Aubagio, Gilenya, Tecfidera, etc.) or injectable (Avonex, Betaseron,
    Copaxone, Rebif, etc.).  If you are on an infusion (Tysabri, Ocrevus)
    you will NOT qualify.
  • Be on your first MS treatment
    unless you recently switched to a second treatment.  

This
research is very easy to participate in. It’s one call with one moderator
talking about your experience.


FACP
gives you a 1–800
number and schedules the call at your convenience and if you do the call, FACP
will donate $200 to MS Views and News (MSVN).


If
you are interested in participating, please email [email protected]  (yes, this is a corrected email address) and reference MSVN.


Doug Lowell
President, Sample Czar
1850 Industrial Street, Suite 514
Los Angeles, CA 90021
direct: 323-717-8117
em: [email protected]  
im: [email protected]
=======================================

RESEARH __ bigstock-Research-and-Development-i.jpg



Disclaimer:
MS Views and News is only providing the information for this
research study.


We will not be involved in the activity nor the results.

Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews